IMA203CD8 in Positive Solid Cancers
12:15 pm - Wednesday 10th February 2027
- Showcasing the manufacturing strategy behind IMA203 to meet the dosing demands of PRAME-positive solid tumours
- Connecting manufacturing innovation with clinical impact by enabling high-dose TCR therapies for solid tumours and supporting the advancement of emerging clinical data in nextgeneration cell therapies
